Skip to content

Nathan Sackett

Department of Psychiatry and Beha vioral Sciences, Center for Novel Therapeutics in Addiction Psychiatry, University of Washington, Seattle, Washington, USA.

4 papers in the library · 5 citations · publishing 2023-2026

Papers

Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.

Psychedelic medicine (New Rochelle, N.Y.) September 1, 2024 Crystal Lederhos Smith, Nathan Sackett, Brian Connor Stark et al. 4 citations

Underground psychedelic-assisted psychotherapy providers described their protocols and perspectives in interviews analyzed through qualitative content analysis. Four themes emerged: personal experiences and self-healing motivated sharing and promoting positive effects of psychedelics as altruism; guides articulated consistent yet flexible processes; guides believed client benefit came from clients' own intrinsic ability to heal; and guides expressed dissonance about legalization, desiring increased access and decreased risk but also concerned about potential negative impacts on provider flexibility and depersonalization from standardization. The findings aim to inform research and policy as psychedelic use expands in the United States.

Bis(4-acetoxy-N-ethyl-N-n-propyltryptammonium) fumarate–fumaric acid (1/1)

IUCrData September 7, 2023 Duyen N. K. Pham, Nathan Sackett, A.r. Chadeayne et al. 1 citation

The crystal structure of a salt formed from a protonated tryptammonium derivative and fumarate was determined using X-ray diffraction. The asymmetric unit contains one singly protonated tryptammonium cation, half of a fumarate dianion, and half of a fumaric acid molecule. In the crystal, these ions and molecules link into infinite chains along the [001] direction through N—H...O and O—H...O hydrogen bonds.

Ibogaine for Opioid Use Disorder: An Unrecognized Risk.

Journal of addiction medicine January 15, 2026 Dale Terasaki, Nathan Sackett, Andrew Monte

Ibogaine, a psychedelic substance, is attracting interest as a potential treatment for opioid use disorder (OUD), with many states funding research. Some proponents frame ibogaine as an alternative to standard, mortality-reducing medications for OUD (MOUD), rather than as a complement. The path to remission varies, but switching from methadone or buprenorphine to an unproven therapy like ibogaine could increase the risk of opioid overdose for some individuals. The addiction medicine community should be aware of this risk and continue to defend evidence-based care while ibogaine is developed.

A Thematic Analysis of the Subjective Effects and Phenomenology of Ibogaine Administered in a Clinical Setting

Research Square November 5, 2025 Joseph la Torre, Step Cheung, Ariana Kam et al.

In a study with 236 participants, the largest sample to date, researchers asked open-ended questions to people in an ibogaine-assisted treatment program in Mexico. Common themes emerged: emotional amplification, life review, perceptual and sensory changes, visionary states, and a sense that ibogaine has its own character or agency. The findings provide a detailed, empirically grounded portrait of ibogaine's subjective effects and show its capacity to evoke structured, meaningful, and potentially transformative states of consciousness. The study's strengths include its large sample, rapid data collection, a safe clinical setting, careful participant preparation, and open-ended questions that captured the full range of experiences.